The HIV therapy market is crowded with many approved antiretroviral (ARV) therapies. Growth in this market is being driven by increasing acceptance of new, high-priced ARVs, particularly the latest single-tablet regimens (STRs), which have enhanced side-effect profiles (e.g., improved safety and tolerability, lower pill burden). The introduction of single-pill nuc-sparing and nuc-reduced regimens (e.g., ViiV's Juluca and Dovato), which have a lower long-term risk of comorbidities, may expand treatment options and allow preferential prescribing to HIV patients who are compliant with their treatment regimens. In addition, the approval of ViiV's Cabenuva in 2021 has ushered in a new era of long-acting regimens that will help eliminate the requirement for lifelong daily pills. Finally, a large and aging predominantly viremic patient population whose requirements will shift to treatment of their comorbidities as their HIV infections are well managed will create new commercial opportunities. This claims data analysis offers insight into the current treatment landscape and physicians’ prescribing practices in HIV.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States.
Key drugs: Biktarvy, Dovato, Juluca, Symtuza, Delstrigo, Rukobia, Trogarzo, Cabenuva, Truvada, Descovy.